Novartis nears $70-plus per share deal to acquire Avidity Biosciences, Bloomberg News reports

Novartis AG is reportedly nearing an acquisition of U.S. biotech Avidity Biosciences for over $70 per share, with an announcement potentially coming as early as Sunday, according to Bloomberg News. This potential deal aligns with Novartis's strategic imperative to bolster its drug pipeline and drive future growth, following recent acquisitions including Tourmaline Bio for $1.4 billion and an agreement to buy Regulus Therapeutics for up to $1.7 billion.

Analysis

Novartis AG (NVS) is reportedly close to acquiring U.S. biotech Avidity Biosciences (RNA) for more than $70 per share, according to Bloomberg News, with an announcement potentially coming as early as Sunday. This news, while speculative due to a lack of immediate comment from either company, suggests a significant premium for Avidity shareholders, driving a strongly positive sentiment for RNA. The overall market impact is assessed as moderately positive, reflecting the potential for a strategic M&A event in the healthcare sector.

This potential acquisition aligns with Novartis's aggressive strategy to bolster its drug pipeline and drive future growth through M&A. The company has demonstrated this commitment with recent deals, including the acquisition of Tourmaline Bio (TRML) for $1.4 billion and an agreement to buy Regulus Therapeutics (RGLS) for up to $1.7 billion earlier this year. These transactions highlight Novartis's focus on expanding its biopharmaceutical portfolio to secure long-term growth.

The reported offer price for Avidity Biosciences indicates a substantial valuation, reflecting the perceived value of its therapeutic pipeline. While the general sentiment is positive, the speculative nature of the report necessitates caution until official confirmation and detailed terms are released. Investors should consider the strategic implications for Novartis's pipeline diversification and the financial impact of another significant acquisition.

Key Decisions for Investors

• Investors holding RNA should monitor for official announcements regarding the acquisition price and potential tender offer details, as a confirmed deal at over $70 per share would imply significant upside from current levels.
• NVS investors should evaluate the strategic fit and financial implications of this potential acquisition, including integration risks and the long-term pipeline benefits, especially given Novartis's recent M&A activity.
• Given the speculative tone, it is prudent to await official confirmation from Novartis or Avidity before making definitive investment decisions based solely on the Bloomberg report.